Literature DB >> 9336303

Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase.

J P Hérault1, A Bernat, A M Pflieger, J C Lormeau, J M Herbert.   

Abstract

Factor Xa, as with thrombin, binds to the clot and contributes to the propensity of thrombi to activate the coagulation system. The aim of this work was to compare the extent of prothrombinase inhibition produced by two factor Xa inhibitors: the antithrombin III-dependent synthetic pentasaccharide (SR 90107/Org 31540) and DX-9065A, a direct factor Xa inhibitor. When incubated together with prothrombin, factor Xa, phospholipids, antithrombin III and calcium, clots formed from human plasma exhibited a prothrombinase activity as measured through fragment 1-2 (F1+2) generation. Ten washes of the clot were required to achieve complete removal of unbound factor Xa. The absence of F1+2 generation brought about by washed clots in buffer when factor V was omitted, or in the presence of annexin V, indicated that they contained bound factor Xa and phospholipids but no factor V/Va. In all tested experimental conditions, clot-bound-factor Xa-induced F1+2 generation was inhibited by SR 90107/AT and DX-9065A with IC50 in the same range of concentrations (0.5 microM). In contrast, the inhibition of prothrombinase formed with factor Xa, factor Va phospholipids and calcium in buffer was observed at significantly lower concentrations of DX-9065A than of SR 90107/AT (respective IC50 concentrations: 0.1 and 70 microM). In vivo, fibrin accretion onto a preformed thrombus as well as venous thrombosis induced in the jugular vein of rabbits was inhibited by SR 90107 and DX-9065A in the same range of concentrations therefore showing that inhibition of clot-bound factor Xa is a predominant factor for the antithrombotic activity of both direct and indirect inhibitors for factor Xa.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9336303

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Jeffrey I Weitz; John W Eikelboom; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver.

Authors:  Y Yamaguchi; K Okabe; J Liang; F Matsumura; H Ohshiro; K Ishihara; T Matsuda; M Takeya; J I Kuratsu; K Mori; S Yamada; M Ogawa
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

3.  Rivaroxaban delivery and reversal at a venous flow rate.

Authors:  Laura M Haynes; Thomas Orfeo; Kenneth G Mann
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-27       Impact factor: 8.311

4.  Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.

Authors:  S S Rebello; R G Bentley; S R Morgan; C J Kasiewski; V Chu; M H Perrone; R J Leadley
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

Review 5.  Newer anticoagulants in 2009.

Authors:  Meyer Michel Samama; Grigoris T Gerotziafas
Journal:  J Thromb Thrombolysis       Date:  2010-01       Impact factor: 2.300

6.  Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee Replacement.

Authors:  Lars C Borris; Morten Breindahl; Michael R Lassen; Akos F Pap
Journal:  Thrombosis       Date:  2011-05-03

Review 7.  The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm.

Authors:  Keren Borensztajn; Jan H von der Thüsen; Maikel P Peppelenbosch; C Arnold Spek
Journal:  J Cell Mol Med       Date:  2009-11-28       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.